Viglip-M (vildagliptin + metformin): Uses, Dosage & Side Effects

What it's for (Indications)

Vildagliptin + Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
This combination therapy is particularly beneficial for patients whose hyperglycemia is not adequately controlled on metformin monotherapy, or who are already being treated with vildagliptin and metformin as separate tablets.
It may also be used as initial therapy in certain patients with type 2 diabetes when diet and exercise alone are insufficient, offering a dual mechanism of action to address various pathophysiological defects.
Its use aims to achieve and maintain target blood glucose levels, thereby reducing the risk of long-term diabetes complications.
The initiation of therapy should always be carefully considered based on the patient's individual clinical profile, including glycemic control status, comorbidities, and tolerance to previous treatments, to ensure optimal therapeutic outcomes while minimizing potential risks.

Dosage Information

Type	Guideline
Standard	The dosage of vildagliptin + metformin must be individualized based on the patient's current regimen, effectiveness, and tolerability, while not exceeding the maximum recommended daily dose of 100 mg vildagliptin and 2000 mg metformin. The usual starting dose for patients not currently on metformin is typically 50 mg vildagliptin/500 mg metformin once daily, gradually titrating to twice daily with meals to minimize gastrointestinal side effects. For patients already on metformin, the starting dose should provide 50 mg vildagliptin twice daily and the metformin dose already being taken. For patients inadequately controlled on metformin monotherapy, the recommended dose is 50 mg vildagliptin twice daily, with the metformin dose adjusted to optimize glycemic control. The tablets should be taken orally, with food, to reduce gastrointestinal upset associated with metformin. Renal function should be assessed prior to initiation and periodically thereafter; specific dose adjustments or contraindications apply based on estimated glomerular filtration rate (eGFR). Hepatic impairment also necessitates caution and potential dose modifications.

Type

Guideline

Standard

The dosage of vildagliptin + metformin must be individualized based on the patient's current regimen, effectiveness, and tolerability, while not exceeding the maximum recommended daily dose of 100 mg vildagliptin and 2000 mg metformin. The usual starting dose for patients not currently on metformin is typically 50 mg vildagliptin/500 mg metformin once daily, gradually titrating to twice daily with meals to minimize gastrointestinal side effects. For patients already on metformin, the starting dose should provide 50 mg vildagliptin twice daily and the metformin dose already being taken. For patients inadequately controlled on metformin monotherapy, the recommended dose is 50 mg vildagliptin twice daily, with the metformin dose adjusted to optimize glycemic control. The tablets should be taken orally, with food, to reduce gastrointestinal upset associated with metformin. Renal function should be assessed prior to initiation and periodically thereafter; specific dose adjustments or contraindications apply based on estimated glomerular filtration rate (eGFR). Hepatic impairment also necessitates caution and potential dose modifications.

Safety & Warnings

Common Side Effects

Commonly reported side effects for vildagliptin + metformin include gastrointestinal disturbances such as nausea, diarrhea, abdominal pain, and vomiting, primarily attributed to the metformin component and often transient, especially with gradual dose titration.
Other frequent side effects may include headache, nasopharyngitis, dizziness, and fatigue.
Hypoglycemia can occur, particularly when this combination is co-administered with a sulfonylurea or insulin, necessitating careful monitoring and dose adjustments of concomitant medications.
Serious, albeit rare, side effects associated with vildagliptin include pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, and hepatic dysfunction.
The metformin component carries a rare but severe risk of lactic acidosis.
Other potential adverse events include joint pain, skin reactions such as bullous pemphigoid, and vitamin B12 deficiency with long-term metformin use.
Patients should be educated on recognizing symptoms of these adverse events and seeking immediate medical attention if they occur.

Serious Warnings

Black Box Warning: This specific combination product (vildagliptin + metformin) does not carry a formal FDA-mandated Black Box Warning. However, it is imperative to acknowledge and highlight several serious warnings that require diligent clinical attention and patient education. The most critical concern is the potential for **Lactic Acidosis**, a rare but severe metabolic complication associated with metformin accumulation, which can be fatal. This risk is significantly elevated in patients with compromised renal function (eGFR < 30 mL/min/1.73m²), dehydration, acute congestive heart failure, sepsis, hepatic impairment, acute myocardial infarction, or heavy alcohol intake. Symptoms such as malaise, myalgia, respiratory distress, increased somnolence, and abdominal pain warrant immediate medical evaluation and discontinuation of the drug. Another serious concern is the risk of **Acute Pancreatitis**, reported with vildagliptin, including fatal cases. Patients should be monitored for characteristic symptoms, such as persistent, severe abdominal pain radiating to the back, potentially with nausea or vomiting, and the drug should be discontinued if pancreatitis is suspected. Additionally, **Hepatic Dysfunction** (elevated liver enzymes) has been observed, necessitating liver function monitoring prior to initiation and periodically during treatment, particularly during the first year. Although not a black box warning, these severe risks necessitate thorough patient counseling, careful patient selection, and ongoing monitoring.
Several critical warnings are associated with vildagliptin + metformin.
The most serious concern is the risk of lactic acidosis due to metformin accumulation, which is a rare but life-threatening metabolic complication.
This risk is increased in patients with impaired renal function, acute congestive heart failure, severe infection, acute myocardial infarction, acute dehydration, or chronic alcohol abuse.
Hepatic dysfunction, including elevated liver enzymes, has been observed with vildagliptin, necessitating liver enzyme monitoring prior to initiation and periodically during treatment.
Acute pancreatitis, including fatal cases, has been reported with vildagliptin, and patients should be advised of the characteristic symptoms (persistent, severe abdominal pain) and to discontinue the medication if suspected.
There is also a risk of vitamin B12 deficiency with long-term metformin use.
Hypoglycemia risk is heightened when used in combination with insulin or sulfonylureas.
Patients undergoing radiological studies involving intravascular iodinated contrast materials or surgical procedures should temporarily discontinue metformin-containing products due to increased risk of lactic acidosis.
Caution is advised in patients with a history of heart failure, as some drugs in the DPP-4 inhibitor class have been associated with heart failure exacerbation.

How it Works (Mechanism of Action)

Vildagliptin + Metformin combines two distinct antihyperglycemic agents with complementary mechanisms of action. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that selectively prevents the degradation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This leads to increased postprandial and fasting concentrations of active incretin hormones, which, in turn, enhance glucose-dependent insulin secretion from pancreatic beta cells and suppress glucagon secretion from pancreatic alpha cells, thereby reducing hepatic glucose production. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, largely through inhibition of gluconeogenesis and glycogenolysis. It also improves insulin sensitivity by increasing peripheral glucose uptake and utilization in muscle and adipose tissue, and reduces intestinal absorption of glucose. Critically, metformin does not stimulate insulin secretion, thus posing a lower risk of hypoglycemia when used as monotherapy. The synergistic effect of these two agents addresses multiple core defects of type 2 diabetes pathophysiology, leading to comprehensive glycemic control.